Skip to main content
Clinical Trials/NL-OMON46655
NL-OMON46655
Completed
Phase 4

Shorter treatment of catheter-related urinary tract infections - SHORTCUT

Academisch Medisch Centrum0 sites300 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Academisch Medisch Centrum
Enrollment
300
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • At presentation with current episode of catheter related urinary tract infection:
  • 1\. Indwelling (transurethral or supra\-pubic) urinary catheter with the intention for long\-term continuous catheterization, at least for the next 28 days
  • 2\. Signs/symptoms of a systemic UTI, following the modified Loeb criteria \[23,24]: a. patient feels sick. b. at least one of the following signs: Fever \> 37\.9 ºC; Rigors; New onset delirium; new/worsened costovertebral angle tenderness or other local signs of UTI; In patients with spinal cord injury: increase of spasticity.
  • 3\. Positive dipstick leucocyte esterase test, or sediment \> 10 leucocytes/mm3\. If a dipstick or sediment was not performed, a positive urine is needed.

Exclusion Criteria

  • 1\. Evidence of acute prostatitis or epididymitis
  • 2\. Insufficient understanding of Dutch or English language, or otherwise unable (cognitively impaired or incapacitated) to understand or cooperate in study, or to give informed consent.
  • 3\. Patients younger than 18 years of age.
  • 4\. Current pregnancy
  • 5\. Patients with kidney transplant.
  • 6\. Patients with suspected concomitant infection requiring antibiotic treatment
  • 7\. Patients with growth of S. aureus or pseudomonas spp in blood culture.
  • 8\. Patients that cannot be treated with (combinations of) the following antibiotics: amoxicillin, amoxicillin/clavulanic acid, cefuroxime, cefotaxime, ceftriaxone, ceftazidime, meropenem, gentamicin, tobramycin, ciprofloxacin, cotrimoxazole, vancomycin.

Outcomes

Primary Outcomes

Not specified

Similar Trials